Nanoscope Therapeutics Press Releases
-
Nanoscope Therapeutics Announces Presentations at the World Orphan Drug Congress
May 22, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting
April 27, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting
April 13, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
March 30, 2023 by Nanoscope Therapeutics
Nanoscope Therapeutics In the News
- Eye on the Cure Podcast Episode #46 : Aaron Osborne, MD, Chief Medical Officer and Chief Development Office of Nanoscope Therapeutics
- Clinical Trials Arena : Nanoscope reveals key efficacy data from Phase IIb ophthalmology trial
- Ophthalmology Times : Nanoscope Therapeutics presents results from phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa
- Global Genes: Nanoscope Reports Positive Topline Results from Phase 2b Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
- Clinical Trials Arena: Nanoscope’s Gene Therapy Nabs Phase II Win in Retinitis Pigmentosa
Upcoming Nanoscope Therapeutics Events
- May 23-25, 2023 | World Orphan Drug Congress | Washington DC
- June 5-8, 2023 | BIO International Convention – Boston
- June 10, 2023 | Clinical Trials at the Summit | Park City, UT
- June 12-13, 2023 | 9th Annual Brain Initiative Meeting
- July 27, 2023 | OIS Retina Innovation Summit | Seattle
- July 28- Aug 1, 2023 | American Society of Retina Specialists Annual Meeting | Seattle
- Oct 5-8, 2023 | 23rd Euretina Congress | Amsterdam
- Oct 11-14, 2023 | The Retina Society Annual Scientific Meeting | New York
- Nov 3-6, 2023 | American Academy of Ophthalmology Annual Meeting | San Francisco